Selective Estrogen Receptor Modulator Raloxifene-Associated Aggravation of Nonalcoholic Steatohepatitis

Toshinari Takamura; Akiko Shimizu; Takuya Komura; Hitoshi Ando; Yoh Zen; Hiroshi Minato; Eiki Matsushita; Shuichi Kaneko

doi:10.2169/internalmedicine.46.6374

CASE REPORTS

Selective Estrogen Receptor Modulator Raloxifene-Associated Aggravation of Nonalcoholic Steatohepatitis

Toshinari Takamura, Akiko Shimizu, Takuya Komura, Hitoshi Ando, Yoh Zen, Hiroshi Minato, Eiki Matsushita, Shuichi Kaneko

Author information

Toshinari Takamura
Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Science
Akiko Shimizu
Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Science
Takuya Komura
Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Science
Hitoshi Ando
Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Science
Yoh Zen
Pathology Section, Kanazawa University Hospital
Hiroshi Minato
Pathology Section, Kanazawa University Hospital
Eiki Matsushita
Department of Internal Medicine, Kahoku Central Hospital
Shuichi Kaneko
Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Science

Keywords: estrogen, estrogen receptor modulators, fatty liver, nonalcoholic steatohepatitis, osteoporosis, postmenopausal

JOURNAL OPEN ACCESS

2007 Volume 46 Issue 9 Pages 579-581

DOI https://doi.org/10.2169/internalmedicine.46.6374

Details

Abstract

A 53-year-old postmenopausal woman, who had a family history of cryptogenic liver cirrhosis, was diagnosed with osteoporosis, and started on the selective estrogen receptor modulator (SERM) raloxifene 60 mg/day orally. She developed marked liver dysfunction. Her body mass index (BMI) was 26.5. Her blood chemistry indicated AST 342 IU/L, ALT 356 IU/L, and hyaluronic acid 255 ng/mL. An oral glucose tolerance test showed impaired glucose tolerance with marked insulin resistance. Histologically, we diagnosed this case as having pre-cirrhotic nonalcoholic steatohepatitis (NASH). This is the first histologically confirmed case of NASH that was aggravated by raloxifene.

Corresponding author

Register with J-STAGE for free!